OBJECTIVE: There is a significant unmet need for serum biomarkers in relapsing-remitting multiple sclerosis (RRMS) that are predictive of therapeutic response to disease-modifying therapies. Following a recent Stanford study which reported that pretreatment levels of serum interleukin (IL)-17F could predict poor response to interferon-β (IFNβ) therapy, we sought to validate the finding using samples from a large clinical trial. METHODS: The validation cohort included 54 good responders (GR) and 64 poor responders (PR) selected from 762 subjects with RRMS from the IM IFNβ-1a dose comparison study (Avonex study C94-805). Subjects were classified as GR and PR based on the number of relapses, Expanded Disability Status Scale score, and new and enlarging T2 lesions on MRI. Serum samples were assayed for IL-17F using a multiplexed Luminex assay and for IL-17F/F using an ELISA. Replicate aliquots from the Stanford study were also assayed to assure reproducibility of methods. RESULTS: Median pretreatment and post-treatment serum IL-17F levels were not statistically significantly different between GR and PR, and serum IL-7/IL-17F ratios were also not predictive of response status. Replicate aliquots from the Stanford study showed good correlation to their original cohort (r = 0.77). CONCLUSIONS: We were unable to validate the finding that serum IL-17F is a predictor of PR in a large independent cohort of subjects with RRMS. Differences in patient populations and methodology might explain the failure to validate the results from the Stanford study.
OBJECTIVE: There is a significant unmet need for serum biomarkers in relapsing-remitting multiple sclerosis (RRMS) that are predictive of therapeutic response to disease-modifying therapies. Following a recent Stanford study which reported that pretreatment levels of serum interleukin (IL)-17F could predict poor response to interferon-β (IFNβ) therapy, we sought to validate the finding using samples from a large clinical trial. METHODS: The validation cohort included 54 good responders (GR) and 64 poor responders (PR) selected from 762 subjects with RRMS from the IM IFNβ-1a dose comparison study (Avonex study C94-805). Subjects were classified as GR and PR based on the number of relapses, Expanded Disability Status Scale score, and new and enlarging T2 lesions on MRI. Serum samples were assayed for IL-17F using a multiplexed Luminex assay and for IL-17F/F using an ELISA. Replicate aliquots from the Stanford study were also assayed to assure reproducibility of methods. RESULTS: Median pretreatment and post-treatment serum IL-17F levels were not statistically significantly different between GR and PR, and serum IL-7/IL-17F ratios were also not predictive of response status. Replicate aliquots from the Stanford study showed good correlation to their original cohort (r = 0.77). CONCLUSIONS: We were unable to validate the finding that serum IL-17F is a predictor of PR in a large independent cohort of subjects with RRMS. Differences in patient populations and methodology might explain the failure to validate the results from the Stanford study.
Authors: M Clanet; E W Radue; L Kappos; H P Hartung; R Hohlfeld; M Sandberg-Wollheim; M F Kooijmans-Coutinho; E C Tsao; A W Sandrock Journal: Neurology Date: 2002-11-26 Impact factor: 9.910
Authors: Robert C Axtell; Brigit A de Jong; Katia Boniface; Laura F van der Voort; Roopa Bhat; Patrizia De Sarno; Rodrigo Naves; May Han; Franklin Zhong; Jim G Castellanos; Robert Mair; Athena Christakos; Ilan Kolkowitz; Liat Katz; Joep Killestein; Chris H Polman; René de Waal Malefyt; Lawrence Steinman; Chander Raman Journal: Nat Med Date: 2010-03-28 Impact factor: 53.440
Authors: Jill F Wright; Frann Bennett; Bilian Li; Jonathan Brooks; Deborah P Luxenberg; Matthew J Whitters; Kathleen N Tomkinson; Lori J Fitz; Neil M Wolfman; Mary Collins; Kyri Dunussi-Joannopoulos; Moitreyee Chatterjee-Kishore; Beatriz M Carreno Journal: J Immunol Date: 2008-08-15 Impact factor: 5.422
Authors: Jan Hilpert; Johanna M Beekman; Susanne Schwenke; Kristin Kowal; David Bauer; Johannes Lampe; Rupert Sandbrink; Jürgen F Heubach; Steffen Stürzebecher; Joachim Reischl Journal: J Neuroimmunol Date: 2008-06-18 Impact factor: 3.478
Authors: Laura E DeForge; Kelly M Loyet; Donnie Delarosa; Jason Chinn; Fojan Zamanian; Anan Chuntharapai; James Lee; Phil Hass; Nathan Wei; Michael J Townsend; Jianyong Wang; Wai Lee T Wong Journal: J Immunol Methods Date: 2010-09-09 Impact factor: 2.303
Authors: M R Sandhya Rani; Jennifer Shrock; Swathi Appachi; Richard A Rudick; Bryan R G Williams; Richard M Ransohoff Journal: J Leukoc Biol Date: 2007-08-20 Impact factor: 4.962
Authors: Kaushal S Gandhi; Fiona C McKay; Stephen D Schibeci; Jonathan W Arthur; Rob N Heard; Graeme J Stewart; David R Booth Journal: J Interferon Cytokine Res Date: 2008-09 Impact factor: 2.607
Authors: Hans-Peter Hartung; Lawrence Steinman; Douglas S Goodin; Giancarlo Comi; Stuart Cook; Massimo Filippi; Paul O'Connor; Douglas R Jeffery; Ludwig Kappos; Robert Axtell; Volker Knappertz; Timon Bogumil; Susanne Schwenke; Ed Croze; Rupert Sandbrink; Christopher Pohl Journal: JAMA Neurol Date: 2013-08 Impact factor: 18.302
Authors: Raquel Alenda; Lucienne Costa-Frossard; Roberto Alvarez-Lafuente; Carmen Espejo; Eulalia Rodríguez-Martín; Susana Sainz de la Maza; Noelia Villarrubia; Jordi Río; María I Domínguez-Mozo; Xavier Montalban; José C Álvarez-Cermeño; Luisa M Villar Journal: J Neurol Date: 2017-10-12 Impact factor: 4.849